Clarity Pharmaceuticals Ltd Market Cap ($414.45 Million)
Market Cap & Net Worth: Clarity Pharmaceuticals Ltd (CU6)
Clarity Pharmaceuticals Ltd market cap. Clarity Pharmaceuticals Ltd (AU:CU6) has a market capitalization of $414.45 Million (AU$585.74 Million) as of November 1, 2026. Listed on the AU stock exchange, this Australia-based company holds position #12871 globally and #336 in its home market, demonstrating a -6.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clarity Pharmaceuticals Ltd's stock price AU$1.57 by its total outstanding shares 373081230 (373.08 Million). Also see CU6 cash flow metrics for how efficiently the company converts equity into cash flow.
Clarity Pharmaceuticals Ltd Market Cap History (2021–2026)
Clarity Pharmaceuticals Ltd market cap history from 2021 to 2026. Data shows growth from $195.34 Million to $414.45 Million (0.88% CAGR). Check Clarity Pharmaceuticals Ltd stock price for real-time trading data and today's change.
Clarity Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clarity Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Clarity Pharmaceuticals Ltd (CU6) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
94.29x
Clarity Pharmaceuticals Ltd's market cap is 94.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $195.34 Million | $3.20 Million | -$10.22 Million | 61.11x | N/A |
| 2022 | $261.34 Million | $6.46 Million | -$23.75 Million | 40.46x | N/A |
| 2023 | $501.56 Million | $9.80 Million | -$24.60 Million | 51.18x | N/A |
| 2024 | $1.10 Billion | $11.51 Million | -$42.32 Million | 95.67x | N/A |
| 2025 | $892.25 Million | $9.46 Million | -$64.30 Million | 94.29x | N/A |
Competitor Companies of CU6 by Market Capitalization
Companies near Clarity Pharmaceuticals Ltd in the global market cap rankings as of November 1, 2026. Also see CU6 total assets for a full breakdown of the balance sheet.
Key companies related to Clarity Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Clarity Pharmaceuticals Ltd (2021–2026)
Market capitalization of Clarity Pharmaceuticals Ltd from 2021 to today. Between 2021 and today, Clarity Pharmaceuticals Ltd's market cap moved from $195.34 Million to $ 414.45 Million, with a yearly change of 0.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$414.45 Million | -53.55% |
| 2025 | AU$892.25 Million | -18.94% |
| 2024 | AU$1.10 Billion | +119.47% |
| 2023 | AU$501.56 Million | +91.92% |
| 2022 | AU$261.34 Million | +33.78% |
| 2021 | AU$195.34 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Clarity Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $414.45 Million USD |
| MoneyControl | $414.45 Million USD |
| MarketWatch | $414.45 Million USD |
| marketcap.company | $414.45 Million USD |
| Reuters | $414.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic rad… Read more